OS Benefit Eludes Second-Line Niraparib Maintenance in Ovarian Cancer
For women with platinum-sensitive recurrent ovarian cancer, maintenance therapy using an individualized starting dose of niraparib (Zejula) did not improve overall survival (OS) despite producing a statistically and clinically significant progression-free survival (PFS) benefit in the phase III NORA study. An interim analysis of the key secondary endpoint showed a median OS of 46.3 months […]